What are your top takeaways in GI Cancers from ASCO 2022?  

1. DYNAMIC study: I believe circulating tumor DNA (ctDNA) will dramatically improve personalized medicine for cancer patients. This study confirmed that ctDNA-based adjuvant chemo treatment significantly decreases the patients who need/are recommended for adjuvant treatment (50% reduction) without c...

1. Dostarlimab in MSI-high locally advanced rectal cancer: Small n=12 but 100% clinical complete response to single-agent anti-PD1 obviated the need for chemoradiation or surgery. Potentially huge implications for both sporadic and germline dMMR rectal Ca!2. DYNAMIC ctDNA guidance of adjuvant therap...

1. @Andrea Cercek - Dostarlimab in MSI-high rectal cancer. Sure we will need longer follow up to get a better understanding on the impact of checkpoint inhibitors in this setting (relapses, when/where they occur, if they occur, etc…). This data is very important also for patients with di...

First pick is not surprising! Dostarlimab's success in MSI-h rectal cancer study demonstrated a remarkable response rate in locally advanced rectal cancer. Longer term follow-up is certainly needed but what is notable is the contrast in response rate for earlier stage vs late stage disease.&n...

Poster 2516, Balachandran et al. - phase I trial of adjuvant autogene cevumeran, an individualized mRNA neoantigen vaccine for pancreatic ductal adenocarcinoma – in the group that got the vaccine with a response no recurrences out to 18 months of follow up (nearly all of the non-responders h...